Telesso Technologies Announces Strategic Clinical Trial with Partner Vascular Pathways on Innovative Guidewire-Assisted Catheter

Telesso Technologies Limited Announces Funding of a Strategic Clinical Trial with Vascular Pathways Inc. an Innovative, FDA-Approved Guidewire-Assisted Peripheral Catheter.

Telesso Technologies Limited (ASX: TEO) announced today it has entered into a strategic agreement with Vascular Pathways, Inc. (VPI), a Delaware company based in California, to fund a multi-center clinical trial of VPI’s guidewire device and to potentially acquire VPI.

A peripheral vein is the most common site for insertion of a catheter for short-term diagnostic or therapeutic use. The catheter is placed into the peripheral vein in the arm, below the elbow and is typically passed up inside the vein to a length of 2-3 inches.

VPI’s technology uses a first-in-class retractable nitinol guidewire system which Telesso anticipates will result in faster and more reliable peripheral IV placement with less patient discomfort. Telesso believes that VPI’s device is the first clinically meaningful advancement in peripheral IV access since automatic needle retraction catheters and addresses significant unmet needs in peripheral intravenous access.

Telesso expects that VPI’s clinical trials will be conducted at world-class hospitals in the US and Israel. Peter Rosenthal, Ph.D., a member of the VPI’s board of directors, commented, "I am delighted to enter into this relationship with Telesso Technologies. Since our technology already has FDA approval, our clinical trial of roughly 300 patients is designed to be a side-by-side comparison with traditional catheters to clearly measure our device’s distinct advantages.” Trial sites have been identified and the trial is scheduled to begin in Q1-2009.

In making the announcement Telesso's Chairman, Michael Hoy, commented, "We are very pleased that our team has identified VPI as a strategic partner. We believe that the market potential for VPI’s device and its potential follow-on products is quite significant. We look forward to reviewing the results of the trial.”

For more information please visit our web site at www.telesso.com.